OncoImmunology · 2021 · 33 citations · 53 references
MedicineImmunologyOncologyImmunotherapyMolecular OncologyTumor MicroenvironmentCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationMetabolic ReprogrammingTumor Microenvironment ModulationCheckpoint Modulation In CancerImmune Checkpoint Ligand ExpressionImmune Checkpoint ReceptorsMicrosatellite Instability AnalysisPd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayTumor Mutational Burden
gene. PPARγ-agonist reduced proliferation and viability of tumor cells in co-cultures with PD-L1 blocking Ab and lymphokine-activated killer cells (LAK) derived from the peripheral blood of CRC patients or healthy donors. Thus, metabolic modifiers improved the antitumoral response of immune checkpoint Ab, proposing novel therapeutic strategies for CRC.
53
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
The consensus molecular subtypes of colorectal cancer
Justin Guinney, Rodrigo Dienstmann, Xin Wang et al. · Nature Medicine · 2015 · 5.3K citations · Full text
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers, Jared Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation · 2017 · 3.9K citations · Full text
Medicine, Immunology, Oncology +17
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Răzvan Cristescu, Robin Mogg, Mark Ayers et al. · Science · 2018 · 2.3K citations
Medicine, Immunology, Oncology +17
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Georgios Vlachogiannis, Somaieh Hedayat, Alexandra Vatsiou et al. · Science · 2018 · 2.1K citations · Full text
Medicine, Oncology, Pharmacology +17